After flow cytometry showed higher GPRC5D levels on MM cells compared with normal plasma cells, talquetamab was found to kill MM cells obtained from bone marrow aspirates of NDMM and double- or triple-class refractory MM patients by redirecting T cells against GPRC5D antigen on the MM cell surface [55]. The gene discussed is GPRC5D; the disease is Miyoshi myopathy.